BlackRock’s Argos Therapeutics, Inc. ARGS Stock Holding History

BlackRock’s Portfolio ARGS Stock Details ARGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-378	Closed	–	–	5204
2018 Q1	$0	Buy	378 +2	+0.5%	+$4	﹤0.01%	5130
2017 Q4	$1K	Buy	376 +23	+7%	+$77	﹤0.01%	4917
2017 Q3	$1K	Buy	353 +40	+13%	+$192	﹤0.01%	4951
2017 Q2	$2K	Sell	313 -39,442	-99%	-$336K	﹤0.01%	4932
2017 Q1	$360K	Buy	39,755 +39,728	+147,141%	+$2.51M	﹤0.01%	4058
2016 Q4	$3K	Hold	27	–	–	﹤0.01%	3625
2016 Q3	$3K	Hold	27	–	–	﹤0.01%	3591
2016 Q2	$3K	Buy	+27	New	+$3.6K	﹤0.01%	3622

Other funds holding ARGS

Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

BlackRock's ARGS Position: Q2 2018 in Review

BlackRock sold out of Argos Therapeutics, Inc. (ARGS) in Q2 2018, closing a stake of 378 shares.

BlackRock first reported a position in ARGS in Q2 2016 and held it in 8 quarters. The position peaked at $360K in Q1 2017. 4 funds tracked by Wall St. Rank hold ARGS as of Q2 2018.

BlackRock reported no remaining Argos Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
BlackRock sold 378 Argos Therapeutics, Inc. shares in Q2 2018.
BlackRock first reported a position in Argos Therapeutics, Inc. in Q2 2016 and held it in 8 quarters.
BlackRock's Argos Therapeutics, Inc. position peaked at $360K in Q1 2017.
4 funds tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q2 2018.

Based on BlackRock's 13F filing for Q2 2018, filed 9 Aug 2018.